[Skip to Content]
[Skip to Content Landing]
Views 241
Citations 0
News From the Food and Drug Administration
April 18, 2017

Nocturnal Polyuria Drug Approved

JAMA. 2017;317(15):1518. doi:10.1001/jama.2017.3344

Desmopressin acetate, a nasal spray marketed as Noctiva, is the first FDA-approved treatment for adults with nocturnal polyuria who awaken at least twice per night to urinate.

A variety of factors can cause nighttime wakening to urinate: congestive heart failure, poorly controlled diabetes mellitus, certain medications, enlarged prostate, overactive bladder, or excessive fluid consumption. Therefore, physicians who prescribe the drug should determine what’s causing a patient’s nocturia and ensure optimal treatment for underlying conditions. Confirming overproduction of urine with a 24-hour urine collection is recommended before physicians suggest that a patient try the drug.

First Page Preview View Large
First page PDF preview
First page PDF preview